ScholarLens Back to search
2003•Unpublished venueRequires access

Humanized Monoclonal Antibody Specific to the Extracellular Domain of PSMA: Dose Escalation Trial in Patients with Prostate Cancer

Shankar Vallabhajosula

Open publisher page 0 citations

Abstract

Prostate specific membrane antigen (PSMA) is the single most well-established, highly restricted prostate epithelial cell membrane antigen expressed by virtually all prostate cancers. PSMA is an ideal target for developing radio labeled monoclonal antibodies (mAbs) for radioimmunotherapy (RIT) of prostate cancer. J591 mAb binds with very high affinity to the extra-cellular domain of PSMA and binds to viable tumor cells. We have previously submitted the final report of the Phase I of the Idea development Award in November 2000.

About this research paper

What this paper is about

Prostate specific membrane antigen (PSMA) is the single most well-established, highly restricted prostate epithelial cell membrane antigen expressed by virtually all prostate cancers. PSMA is an ideal target for developing radio labeled monoclonal antibodies (mAbs) for radioimmunotherapy (RIT) of prostate cancer. J591 mAb binds with very high affinity to the extra-cellular domain of PSMA and binds to viable tumor cells. We have previously submitted the final report of the Phase I of the Idea development Award in November 2000.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Prostate specific membrane antigen (PSMA) is the single most well-established, highly restricted prostate epithelial cell membrane antigen expressed by virtually all prostate cancers. PSMA is an ideal target for developing radio labeled monoclonal antibodies (mAbs) for radioimmunotherapy (RIT) of prostate cancer. J591 mAb binds with very high affinity to the extra-cellular domain of PSMA and binds to viable tumor cells. We have previously submitted the final report of the Phase I of the Idea development Award in November 2000.

Key concepts: Prostate cancer, Monoclonal antibody, Extracellular, Medicine, Monoclonal, Cancer research, Humanized antibody, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Humanized Monoclonal Antibody Specific to the Extracellular Domain of PSMA: Dose Escalation Trial in Patients with Prostate Cancer — Research Paper | ScholarLens